The need for renal replacement therapy is currently rising at an annually increasing rate.
Current treatment options for patients with end-stage kidney disease include dialysis or organ transplantation. Yet, even though transplant survival has increased due to refined immunosuppressive therapy, morbidity remains high because of organ shortage. Here we discuss a recent publication that describes the transplantation of a bioengineered biocompatible kidney from a decellularized organ scaffold, thus possibly providing a solution to both transplant organ shortage and morbidity associated with long-term immunosuppression.
Written by:
Kuppe C, Berger K, Smeets B. Are you the author?
Department of Nephrology and Immunology, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
Reference: Int Urol Nephrol. 2013 Oct 5. Epub ahead of print.
doi: 10.1007/s11255-013-0570-4
PubMed Abstract
PMID: 24097276
UroToday.com Renal & Vascular Diseases Section
